CDK4/6 inhibitor – therapeutic option in triple-negative breast carcinoma?

A new study provides insights into the mechanisms of resistance in triple-negative breast carcinoma (TNBC) and therapy with CDK4/6 inhibitors. Previously known from the treatment regimen of advanced hormone receptor (HR)-positive, HER2-negative breast cancer, a subtype of TNBC also shows sensitivity in this preclinical study.